FY2025 EPS Estimates for MiMedx Group Cut by Northland Capmk

MiMedx Group, Inc. (NASDAQ:MDXG) – Investment analysts at Northland Capmk lowered their FY2025 earnings per share (EPS) estimates for shares of MiMedx Group in a note issued to investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.28 per share for the year, down from their prior estimate of $0.30. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%.

MDXG has been the topic of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $8.10 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.94. The business’s 50-day simple moving average is $8.68 and its 200-day simple moving average is $7.75. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14.

Institutional Trading of MiMedx Group

Several hedge funds have recently added to or reduced their stakes in MDXG. IMG Wealth Management Inc. bought a new stake in MiMedx Group during the 4th quarter valued at approximately $28,000. Blue Trust Inc. bought a new stake in shares of MiMedx Group in the 3rd quarter worth approximately $30,000. Virtus Fund Advisers LLC bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $35,000. Van ECK Associates Corp bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $40,000. Finally, Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after acquiring an additional 4,275 shares during the period. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.